We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.
Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.
We are pleased that after the long COVID lockdown we were able to visit the south African sites to touch base and to discuss the conduct of the trial and potential improvements. We thanks all centres for their warm welcome and their hospitality during our stay and hope that, once everything is more or less back to normal, we’ll meet more often in person again.
Milestone achieved: 50% recruitment for a large African trial against tuberculosis in neonates completed
We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the recruitment of 50 % of all participants.
Did you know that the 100-year-old BCG is the only vaccine available to protect against TB, and the world urgently needs a better TB vaccine?
There are several vaccine candidates in the pipeline, and our VPM1002 is one of the most advanced ones. The Scientist reported about the latest updates in the TB vaccine development. Click here to read the full article.
We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.
Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant
Vakzine Projekt Management supports Memo Therapeutics AG in the clinical development of MTX-COVAB, human-derived antibody against SARS-CoV-2 which has shown excellent neutralizing efficacy against both the original virus as well as the UK variant.